Toyoaki Hida

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp et al. · The Lancet · 2016 · 4.8K citations · Full text

Medicine, Oncology, Pharmacology +13

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer

Jürgen Wolf, Takashi Seto, Ji‐Youn Han et al. · New England Journal of Medicine · 2020 · 997 citations · Full text

Medicine, Oncology, Pharmacology +15

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

Tetsuya Mitsudomi, Takayuki Kosaka, Hideki Endoh et al. · Journal of Clinical Oncology · 2005 · 958 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo et al. · The Lancet · 2017 · 912 citations

Medicine, Oncology, Pharmacology +14